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Abstract: In this paper we describe a two-component BRET (bioluminescence resonance energy
transfer)-based method to detect vascular endothelial growth factor (VEGF) molecules in unknown
samples as the basis for subsequent in vivo use. A luminescent VEGF binding molecule, which
binds in the receptor binding motif of VEGF, is used as the energy donor, transferred to a
fluorophore-coupled VEGF binding molecule (acceptor), which binds to the neuropilin binding
motif of VEGF, thus enabling energy transfer from the donor to the acceptor molecule. This leads to
the emission of light at a longer wavelength and thus the generation of an increased BRET signal
only when VEGF is bound to both the donor and acceptor molecules. We further describe a novel
BRET pair that uses the Renilla reniformis mutant luciferase RLuc8 and the chemically engineered
fluorophore PerCP-Cy5.5®, which exhibits superior peak separation of approximately 300 nm. The
implantation of capsules consisting of the two BRET components in solution, permeable for VEGF
for its in vivo detection, would provide a new and improved method for monitoring VEGF-induced
pathologies and thus an adjustment of therapy to patient needs.
Keywords: VEGF; neuropilin; BRET; ranibizumab; single chain variable fragment (scFv); RLuc8;
PerCP-Cy5.5®
1. Introduction
Resonance energy transfer (RET), a principle first characterized by Theodore Foerster in 1948,
describes the transfer of energy by spectral overlapping [1]. Fluorescence resonance energy transfer
(FRET) has expanded applications in laboratories through the development of coupling fluorescent
probes to biomolecules such as proteins or DNA [2]. FRET uses a fluorescent donor which transfers
energy to a suitable fluorescent acceptor by overlapping the donor’s emission wavelength with the
acceptor’s excitation wavelength, which emits light again at higher wavelengths. Bioluminescence
resonance energy transfer (BRET) uses the same principle, but the donor is replaced by a bioluminescent
luciferase instead of a fluorescent donor. The bioluminescent luciferase, as a catalytic enzyme, produces
a light emission by converting its substrate, and generates an emission peak that can be used to excite
a fluorophore [3]. Several suitable BRET pairings have been described with different donor luciferases
(e.g., Renilla reniformis luciferase, firefly luciferase or click beetle luciferase) using different substrate
analogues for light/energy generation and different acceptors (e.g., protein fluorophores or chemical
fluorophores) (Table 1) [3–6]. The efficacy of energy transfer depends on how close the maximum of
the donor emission overlaps the maximum of the acceptor excitation, the proximity of the donor to
the acceptor and the distance between the donor and the acceptor. [7]. The measured acceptor signal,
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generated by energy transfer, depends on the spectral separation of the maximum donor and acceptor
emission peaks (∆λem) and the orientation of the donor to the acceptor [4,5,8]. BRET systems have
been widely used to understand and monitor protein-protein interactions such as in G-protein–coupled
tyrosine kinase receptors, conformational changes in proteins, the quantification of protein binding
molecules in vitro and in vivo or analyzing protease activity [2,7–11].
Table 1. Different BRET pairs used in protein research. Bioluminescence resonance energy transfer
(BRET), Renilla reniformis luciferase (RLuc), enhanced yellow fluorescent protein (eYFP), green
fluorescent protein (GFP), red fluorescent protein (RFP), fluorescent protein (FP), coelenterazine (CLZ),
mutated Renilla reniformis luciferase (RLuc8), red-shifted Renilla reniformis luciferase mutant (RLuc8.6).
Name Energy Donor Energy Acceptor Luciferase Substrate Spectral Resolution
∆λem (nm) Ref.
BRET 1 RLuc eYFP n-CLZ 50 [3]
BRET 2 RLuc GFP2 CLZ400a 115 [6]
eBRET 2 RLuc8 GFP2 CLZ400a 115 [4]
BRET 3 RLuc8 mOrange n-CLZ 85 [5]
BRET 3.1 RLuc8 mOrange CLZ-v 50 [5]
BRET 4.1 RLuc8 TagRFP CLZ-v 70 [5]
BRET 5 RLuc8.6 TagRFP n-CLZ 50 [5]
BRET 6 RLuc8.6 TurboFP n-CLZ 100 [5]
BRET 6.1 RLuc8.6 TurboFP CLZ-v 65 [5]
BRET 7 RLuc8 PerCP-Cy5.5 n-CLZ 300
Personalized medicine is the current key word in optimizing therapy to patient needs in terms
of diagnosis-correlated therapy. Therefore, “labs on a chip” or biosensors are currently under
development to achieve improved, personalized therapy options for a variety of different disorders.
Especially in neovascular diseases of the eye such as age-related macular degeneration (AMD),
retinopathy of prematurity (ROP), and diabetic retinopathy (DR), treatment personalization would be
of great benefit to the patients. A typical feature common to these diseases is the hypoxia-induced
upregulation of vascular endothelial growth factor (VEGF) expression which leads to the formation
of new, but immature blood vessels in the eye which may impair visual function. VEGF, as a strong
mitogenpromoting vessel growth, consists of three different receptor binding motifs enabling VEGF
binding to VEGF receptor −1, −2 and neuropilin, which has been supposed to act as a co-receptor
stabilizing VEGF receptor binding due to a lack of intracellular signaling [12]. Newer findings describe
the neuropilin receptor as an activator of the ABL1 pathway [13]. Neuropilin binding is common to all
angiogenic VEGF-A isoforms and is mediated through a C-terminal peptide sequence.
The current state-of-the-art treatment paradigm is a monthly injection of so-called anti-VEGF
molecules (Avastin®, Lucentis®, EYELEA®), preventing VEGF binding to the VEGF receptors,
thus decreasing activation of VEGF-induced intracellular signaling. The VEGF level varies from
patient to patient and also during the disease course. The diagnostic parameters, such as visual
acuity (VA) and ocular spectral optical coherence tomography (spectral OCT), used for monitoring
the success of the therapy may indicate a rise in VEGF with delay, when VEGF inhibition is already
decreasing. Another aspect is the different response to these anti-VEGF molecules which also varies
among patients [14]. Many different methods for the detection and quantification of VEGF, such as
ELISAs (enzyme linked immunosorbent assays) or biosensors also using different methods, have been
described so far. All of them are designed for in vitro use after invasive sampling [15,16]. In this regard,
a noninvasive, in vivo method to measure VEGF concentrations would greatly improve personalized
anti-VEGF treatment regimes.
The aim of this study was to establish a new BRET pair, consisting of a mutant of the
Renilla reniformis luciferase (RLuc8) (λem = ~480 nm) in combination with its substrate coelenterazine
(native or n-CLZ) as an energy donor with PerCP-Cy5.5® (λex = ~488 nm, λem = ~700 nm), a chemically
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engineered fluorescent dye, as an energy acceptor (Figure 1A). RLuc8, a mutated wild type RLuc
(A55T, C124A, S130A, K136R, A143M, M185V, M253L, S287L), with increased stability and quantum
yield was used. RLuc8, the parental construct for random mutagenesis, resulted in the red-shifted
variant RLuc8.6 [4]. RLuc8 was fused to a single-chain variable fragment (scFv) based on Ranibizumab
(Ra02, [10]) which binds to the VEGF receptor binding motif of VEGF located at the N-terminus of
VEGF and PerCP-Cy5.5® coupled to the recombinant neuropilin receptor, which in turn binds to the
C-terminal neuropilin motif of VEGF. The combination of this donor and acceptor exhibited superior
spectral separation properties (∆λ = ~300nm; Table 1). Further, we tested different experimental setups
applicable for VEGF detection based on the principle of the ALPHALISA® technology (Perkin Elmer,
Hamburg, Germany) where a dual antibody system is used for VEGF quantification. The system we
propose for VEGF detection is meant to be applicable in vivo, immobilized in an implantable device in
the eye to monitor actual VEGF levels in patients in order to adjust anti-VEGF doses to patient needs,
i.e., to personalize the treatment of neovascular diseases.
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Figure 1. Schematic representation of the BRET principle and expression constructs. (A) RLuc8 
converting n-CLZ and thus generating an emission peak (~490 nm) overlapping the excitation peak 
of PerCp-Cy5.5®, transferring energy to the fluorophore which is emitting light at ~700 nm; (B) BRET 
donor expression construct containing the luciferase RLuc8 and the VEGF binding domain Ra02 fused 
directly or separated with a 4× glycine peptide-linker, under the control of a CMV (cytomegalovirus) 
promoter and a polyadenylation signal (pA) sequence at the 3´-end. 
2. Material and Methods 
2.1. Preparation of BRET Constructs 
An anti-VEGF single chain variable fragment (scFv) (Ra02) (Figure 1B) was used to generate the 
BRET donors by deletion of the secretory IgG kappa leader sequence from the anti-VEGF open 
reading frame (ORF), and by fusing RLuc8 either directly to the N-terminus or separated with a 
peptide linker (4× glycine). 
The fluorescent dye PerCP-Cy5.5® (Lightning Link, Cambridge, UK) was coupled to carrier free 
recombinant neuropilin-1 (NRP-1) (R&D Systems, Wiesbaden, Germany) according to manufacturer 
instructions to generate the BRET acceptor. In brief, 1 µL of LL-modifier was added to 10 µL of carrier-
free neuropilin 1 (1.0 µg/µL). The whole sample was mixed and pipetted to the lyophilized Lightning 
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frame (ORF), and by fusing RLuc8 either directly to the N-terminus or separated with a peptide linker
(4× glycine).
The fluorescent dye PerCP-Cy5.5® (Lightning Link, Cambridge, UK) was coupled to carrier free
recombinant neuropilin-1 (NRP-1) (R&D Systems, Wiesbaden, Germany) according to manufacturer
instructions to generate the BRET acceptor. In brief, 1 µL of LL-modifier was added to 10 µL of
carrier-free neuropilin 1 (1.0 µg/µL). The whole sample was mixed and pipetted to the lyophilized
Lightning Link mix. After incubation at room temperature for 3 h, 1 µL of LL-quencher FD reagent
was added per 10 µL. After additional incubation for 30 min, the conjugates were ready for use or
stored at −20 ◦C.
2.2. Cell Culture and BRET Donor Expression
HEK293 (ATCC: CRL-1573) were cultured in DMEM (Dulbeccos modified eagle media)
supplemented with penicillin/streptomycin, l-glutamine (200 mM) and 10% fetal bovine serum (FBS)
(all purchased from PAN Biotech, Aidenbach, Germany). The cells were transfected with the BRET
donor plasmid DNA (4 µg each) using Lipofectamine 3000 (Life Technologies, Darmstadt, Germany).
Expression was carried out at 37 ◦C, 5% CO2 in a humidified incubator for 24 h. After expression
cells were washed twice with phosphate buffered saline (PBS) and collected in luciferase lysis buffer
(Promega, Mannheim, Germany). After two additional freeze-thaw cycles in liquid nitrogen, the crude
lysate was cleared with centrifugation at 4 ◦C at 14,000 g for 5 min. The supernatant was transferred
into a fresh tube and stored at −20 ◦C prior further analysis.
2.3. RLuc8 Activity
Equal amounts (10 µL) of each BRET donor (RLuc8-Ra02 and RLuc8-4xGly-Ra02) containing
lysate were analyzed for luciferase expression. Native coelenterazine (n-CLZ, NanoLight Inc., Pinetop,
AZ, USA) stock (1.0 mg/mL in 100% ethanol) was diluted in BRET assay buffer (PBS supplemented
with 1.0 g/L d-glucose-monohydrate (Roth, Karlsruhe, Germany), 0.1 g/L calciumchloride-dihydrate
(Merck, Darmstadt, Germany) and 0.1 g/L magnesium chloride heptahydrate (Merck, Darmstadt,
Germany)) and allowed to stabilize for 20 min. The lysates were plated onto COSTAR Lumiplates
Flat White (Corning, Berlin, Germany) and 100 µL of the substrate containing BRET assay buffer were
added to each BRET donor. Luciferase light output was measured immediately after substrate addition
using Tecan Infinite M1000Pro (Tecan, Groeding, Austria) with an integration time of 1 s.
2.4. Western Blot Analysis
Equal amounts of lysates (20 µL) were separated on a 10% Tris-HCL SDS-PAGE and transferred
to a nitrocellulose membrane. Membrane was incubated with rabbit anti-RLuc (Biomol, Hamburg,
Germany) as first antibody and goat anti-rabbit-IgG-HRP (Sigma Aldrich, Taufkirchen, Germany) as
secondary antibody. Rabbit anti-GAPDH (glyceraldehyde-3-phosphate dehydrogenase) (R&D Systems,
Wiesbaden, Germany) in combination with goat anti-rabbit-IgG-HRP was used as loading control.
2.5. Experimental Setup VEGF Detection
According to the schematic representation (Schemes 1–3 different setups for VEGF (rhVEGF165
produced in HEK293; Acro Bioscience; London, UK) detection were tested.
Scheme 1, where the donor molecule or the acceptor molecule are fixed onto a solid surface
(Nunc Maxisorb 96-well plates, Roskilde, Denmark), before a blocking procedure with 1% gelatin
in 1× tris-buffered saline (TBS) and followed by incubation with VEGF and detection with the
BRET donor/acceptor, according to the set-up of an ELISA (enzyme linked immunosorbent assay).
Washing steps were performed with phosphate buffered saline (PBS) supplemented with 0.05% Tween
20 (Sigma Aldrich, Taufkirchen, Germany).
Additionally to Scheme 1, a pre-incubated version where one of the two components (donor or
acceptor), is incubated before the addition of VEGF and the second component (Scheme 2). In Scheme 3
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both components were incubated simultaneously with VEGF. Both, donor and acceptor molecules
were used in excess with a VEGF concentration of 22.4 nM (1.0 µg/mL). For the VEGF concentration
depended measurements, VEGF was diluted with PBS, no VEGF control experiments were performed
with PBS alone.Sensors 2017, 17, 145 5 of 10 
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2.6. Measurement and Calculation of BRET Ratios
BRET measurement , after incubation with VEGF or no VEGF controls, were performed with
two different transmission filters, a blue filter for the measurement of RLuc8 emission (500–560 nm)
and a magenta filter for the detection of the PerCP-Cy5.5® signal (>600 nm). BRET ratio calculations
were done according th BRET Equation (1). Controls with no VEGF incubations were used for
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normalization of the BRET ratios. Mean BRET ratios of samples containing VEGF, or no VEGF as
control, were calculated with measurements in triplicates plus standard deviation.
BRET Ratio =
Biosensor (Magenta filter)
Biosensor (Blue filter)
(1)
2.7. Statistics
All data are reported as mean± standard deviation (SD). Experiments were measured in triplicates
of at least two unrelated biological samples unless otherwise stated. Student´s t-test was used in all
comparisons with SigmaPlot (Systat Software Inc.; Erkrath, Germany). p-values < 0.05 were considered
as statistically significant.
3. Results and Discussion
3.1. Construct Generation, Expression and Functionality of Donor Molecules
The scFv Ra02 was used as the parental expression construct to generate the luminescent VEGF
binding donor molecules [10]. The secretory IgG kappa leader sequence was deleted from the Ra02
VEGF binding domain open reading frame (orf) by PCR mutagenesis. The RLuc8 open reading frame
was inserted at the 5′-end of the Ra02 orf, after the intrinsic stop codon was deleted, to generate the
directly fused variant of the donor expression construct. The 4× glycine donor expression construct
was generated with PCR mutagenesis by inserting a DNA sequence coding for 4× glycine (GGC GGA
GGC GGA) (Figure 1B). Both expression construct orfs were confirmed by using Sanger sequencing.
After transfection and expression in HEK293 for 24 h, the activity of the RLuc8 was confirmed
in a luciferase assay in crude but cleared cell lysate after the addition of 6.3 µM n-CLZ (Figure 2A).
Both donor molecules as well as the RLuc8 alone, as a positive control, showed RLuc8 activity.
Measured light outputs generated by the luciferases were 1494.933 × 103 ± 74.120 × 103 RLU for
the directly fused RLuc8-Ra02 and 98.700 × 103 ± 8.614 × 103 RLU for the 4× glycine variant
RLuc8-4xGly-Ra02. Negative control was measured as 185 ± 15 RLU. Due to the smaller size of
the positive control, RLuc8 was expressed in higher amounts which led to a higher luciferase signal
in this experiment as well as in the Western blot experiment, where equal amounts of cell lysates
were separated.
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binding donor molecules. Expression compared to GAPDH. 
Western blot analysis was performed to show the full-length expression of both BRET donor 
constructs. GAPDH (glycerinealdehyd-3-phosphat-dehydrogenase) was used as a loading control 
(Figure 2B). Expressed donor molecules were located, at the correct size of approximately 90 kDa, on 
the blot (calculated size: 87.9 kDa) and were expressed in nearly equal amounts compared to GAPDH. 
Figure 2. (A) RLuc8 a tivi y of the don r molecule co ts expre sed in HEK293 compared to a
non-DNA transfection serv d as negative control (neg.ct . . Luc8 transfection served as positive
control (pos. ctrl.). Luciferase activities were measured in triplicate, two samples were used to calculate
mean RLU ± SD. (B) Confirmation of full-length expression of the RLuc8 containing VEGF binding
donor molecules. Expression compared to GAPDH.
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Western blot analysis was performed to show the full-length expression of both BRET donor
constructs. GAPDH (glycerinealdehyd-3-phosphat-dehydrogenase) was used as a loading control
(Figure 2B). Expressed donor molecules were located, at the correct size of approximately 90 kDa, on the
blot (calculated size: 87.9 kDa) and were expressed in nearly equal amounts compared to GAPDH.
These results confirm full-length expression as well as the ability of generating light/energy by
coelenterazine conversion.
3.2. BRET Ratios of Different Experimental Setups
BRET ratios of the VEGF binding donor and the corresponding acceptor molecules were assessed
for the three different experimental setups with VEGF or no VEGF as controls.
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for correspondi no-VEGF controls. (A) D no or acceptor molecules fixed onto a solid surface
according to Scheme 1; (B) Donor or acceptor pre-incubation with VEGF according to Scheme 2;
(C) Simultaneous donor and acceptor incubation with VEGF generating significantly different (p < 0.05)
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measured in triplicate, two unrelated biological samples were used to calculate mean values ± SD for
Schemes 1 and 2.
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Fixing the VEGF binding donor molecule or the VEGF binding acceptor molecule did not result in
a significant increase of the BRET ratio after incubation with VEGF compared to the no-VEGF control
for both donor molecules used (Figure 3A). The measured BRET ratios for the donor fixed setup were
1135 ± 189.5 mBU (milli BRET Units) in the no-VEGF control and 1341 ± 280.9 mBU after VEGF
incubation for the combination of RLuc8-Ra02 and NRP1-PerCP-Cy5.5®, and 1023± 191.6 mBU for the
control and 1004 ± 192.6 mBU after VEGF incubation for the RLuc8-4xGly-Ra02/NRP1-PerCP-Cy5.5®
combination. Fixing the acceptor molecule NRP1-PerCP-Cy5.5® resulted in a BRET ratio of
124.1 ± 2.0 mBU for the no-VEGF control, and 124.2 ± 5.2 mBU after VEGF incubation for the
RLuc8-Ra02 donor molecule. For the RLuc8-4xGly-Ra02 donor molecule, the BRET ratios were
128.7 ± 2.2 mBU for the control and 125.4 ± 4.1 for the VEGF sample.
Due to the unreproducible coating procedure of the molecules to the solid surface in combination
with the following blocking procedure and the additional washing steps in this method, this setup is
totally unsuitable for the reliable detection of VEGF in samples with unknown VEGF concentrations.
Another explanation is that the VEGF molecules, as anti-parallel homo-dimers, have two binding
motifs for Ra02 as well as for NRP1 [17]. In the first setup, there is the possibility that both Ra02
and NRP1 binding motifs were already saturated with just donor or acceptor molecules, making it
impossible for the corresponding donor/acceptor molecule to bind to VEGF due to steric inhibition.
VEGF was not able to bind NRP-1 after incubation/saturation with ranibizumab in a NRP-1 binding
assay (unpublished data).
When VEGF was pre-incubated with the donor or the acceptor molecules, the BRET ratio
also did not show a significant increase compared to the control for both donor molecules
(Figure 3B). BRET ratios were calculated as 115.5 ± 3.9 mBU for the donor pre-incubated
RLuc8-Ra02/NRP1-PerCP-Cy5.5® combination incubated with VEGF and 129.4 ± 9.7 mBU for the
no-VEGF control. The donor pre-incubated combination of RLuc8-4xGly-Ra02/NRP1-PerCP-Cy5.5®
was measured as 117.7 ± 1.6 mBU when incubated with VEGF and as 115.0 ± 1.1 mBU with no VEGF.
Pre-incubation with the acceptor molecules resulted in similar results, 143.4 ± 1.9 mBU for the
molecules pre-incubated with VEGF and 146.4 ± 1.5 mBU for the control using the RLUC8-Ra02
variant. 158.1 ± 0.1 mBU was measured for molecules using the RLUC8-4xGly-Ra02 variant for VEGF
detection and 158.1± 1.5 mBU for the control. Here the effect of steric inhibition was more present than
in the fixed method [16]. Although binding of these molecules is always described by a combination of
association and dissociation, there is just little chance to replace one of the molecules with one another.
Nevertheless, no measureable increase in the BRET ratio occurred due to this process for both donor
molecules tested.
The simultaneous incubation of VEGF with both components of the biosensor system resulted
in a significant increase (p < 0.05) in the BRET ratio due to the binding of the molecules and the
transfer of energy from the donor molecule to the acceptor compared to the controls. In the case of the
simultaneous incubation of VEGF with the VEGF binding donor and acceptor molecules, there is a
higher chance for the two different molecules to bind to the same VEGF molecule and also a higher
chance for detecting a BRET signal. Comparable affinity constants for donor and acceptor molecules
are a requirement for consistent results in VEGF detection. The theoretical affinity constant for NRP1
to VEGF was determined as 0.3 pM and Ra02 was characterized with an affinity constant of 1.3 nM in
our previous works on the scFv Ra02 [10,18,19].
Finally, we had a closer look at different VEGF concentrations measured with Scheme 3,
after simultaneous incubation (Figure 4). Here, again, significantly different BRET ratios
compared to the no-VEGF controls were observed for both variants of donor molecules.
(RLuc8-Ra02/NRP1-PerCP-Cy5.5®: 115.3 ± 5.0 mBU for 22.4 nM VEGF, 110.5 ± 2.0 mBU for 11.2 nM
VEGF and 98.7 ± 1.2 mBU for the control; RLuc8-4xGly-Ra02/NRP1-PerCP-Cy5.5®: 119.4 ± 4.0 mBU
for 22.4 nM VEGF, 114.2 ± 5.0 mBU for 11.2 nM VEGF and 101.4 ± 2.2 mBU for the control).
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The specificity of the BRET assay after simultaneous incubation for VEGF-A was ensured by
the use of the Ra02 binding domain of the donor molecule, which is based on ranibizumab, a VEGF
inhibitor used in clinics for years now to block VEGF-induced neovascularization, and the use of NRP-1,
which only binds to the C-terminal part of VEGF-A. The system described here cannot distinguish
between the VEGF-A splice variants containing the angiogenic terminal NRP-1 site and the VEGF
receptor -1 and -2 motifs, where ranibizumab is bound [20].
In this proof-of-concept study, we added b th donor and cceptor molecules in excess, but for
more precise results in the future, especially for use in implantable devices, adjustments regarding
donor and acceptor concentrations to this method will be necessary.
4. Conclusions
In summary, a two-component BRET system to detect VEGF was successfully developed.
In addition, we are the first to describe that RLuc8 is able to transfer energy to the chemical fluorophore
PerCP-Cy5.5®, which leads to a measureable BRET signal. We show that it is possible to detect VEGF in
solution with simultaneous incubation of the VEGF binding donor and acceptor molecules. Our results
are a small but encouraging step forward in the development of an implantable biosensor device
to dete t r even quantify the mitogen VEGF in vivo to onitor VEGF- nduced diseases in the eye.
This will be useful to adjust treatment with anti-VEGF molecules to patient needs.
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